Meg Jardine's Publications

Sarraju A, Li JW, Cannon CP et alii
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial

Journal articles
2021
American Heart Journal
Kang A, Jardine MJ
SGLT2 inhibitors may offer benefit beyond diabetes

Journal articles
2021
Nature Reviews Nephrology
Oshima M, Hara A, Toyama T et alii
Comparison of Circulating Biomarkers in Predicting Diabetic Kidney Disease Progression With Autoantibodies to Erythropoietin Receptor

Journal articles
2021
Kidney International Reports
Yu J, Zhou Z, Mahaffey KW et alii
An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials

Journal articles
2021
International Journal of Cardiology
Neuen BL, Arnott C, Perkovic V et alii
Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes

Journal articles
2021
Diabetes
Evans RDR, Smyth B, Levin A et alii
The International Society of Nephrology Advancing Clinical Trials (ISN-ACT) Network: current activities and future goals

Journal articles
2021
Kidney International
Neuen BL, Ohkuma T, Neal B et alii
Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program

Journal articles
2021
American Journal of Kidney Diseases
Athavale A, Morris J, Jardine M et alii
Acute interstitial nephritis and nephrogenic diabetes insipidus following treatment with sulfamethoxazole-trimethoprim and temozolomide

Journal articles
2021
Nephrology
Li C, Zhou Z, Neuen BL et alii
Sodium-glucose co-transporter-2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and meta-analysis

Journal articles
2021
Diabetes
Bakris G, Oshima M, Mahaffey KW et alii
Effects of canagliflozin in patients with baseline eGFR <30 ml/min per 1.73 m2: Subgroup analysis of the randomized CREDENCE trial

Journal articles
2020
Clinical Journal of the American Society of Nephrology
Sukkar L, Young T, Jardine MJ
How Do the Recent Major Randomized Controlled Trials Inform Best Use of the Novel Glucose-Lowering Agents?

Journal articles
2020
Kidney and Blood Pressure Research
Zhang H, Rogers K, Sukkar L et alii
Prevalence, incidence and risk factors of diabetes in Australian adults aged ≥45 years: A cohort study using linked routinely-collected data

Journal articles
2020
Journal of Clinical and Translational Endocrinology
Oshima M, Neuen BL, Li JW et alii
Early change in albuminuria with canagliflozin predicts kidney and cardiovascular outcomes: A post hoc analysis from the Credence trial

Journal articles
2020
Journal of the American Society of Nephrology
Toussaint ND, Pedagogos E, Lioufas NM et alii
A randomized trial on the effect of phosphate reduction on vascular end points in CKD (improve-CKD)

Journal articles
2020
Journal of the American Society of Nephrology
Smyth B, Chan CT, Grieve SM et alii
Response to: Loutradis et al. Longer Dialysis Sessions Improve Cardiac Systolic Function by Reducing Myocardial Stunning

Journal articles
2020
Journal of Cardiac Failure
Oshima M, Neuen BL, Jardine MJ et alii
Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial

Journal articles
2020
The Lancet Diabetes and Endocrinology
Xie Y, Baker J, Young T et alii
Therapy escalation following an elevated hba1c in adults aged 45 years and older living with diabetes in Australia: A real-world observational analysis

Journal articles
2020
Diabetes Care
Arnott C, Neuen BL, Heerspink HJL et alii
The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program

Journal articles
2020
International Journal of Cardiology
O’Lone E, Howell M, Viecelli AK et alii
Identifying critically important cardiovascular outcomes for trials in hemodialysis: An international survey with patients, caregivers and health professionals

Journal articles
2020
Nephrology Dialysis Transplantation
Clase CM, Fu EL, Ashur A et alii
Forgotten Technology in the COVID-19 Pandemic: Filtration Properties of Cloth and Cloth Masks—A Narrative Review

Journal articles
2020
Mayo Clinic Proceedings
Levin A, Agarwal R, Herrington WG et alii
International consensus definitions of clinical trial outcomes for kidney failure: 2020

Journal articles
2020
Kidney International
O’Hara DV, Neuen BL, Jardine MJ
Kidney and cardiovascular protection with SGLT2 inhibitors: lessons from cardiovascular outcome trials and CREDENCE

Journal articles
2020
Journal of Nephrology
Smyth B, Zuo L, Gray NA et alii
No evidence of a legacy effect on survival following randomization to extended hours dialysis in the ACTIVE Dialysis trial

Journal articles
2020
Nephrology
Zhu B, Jun M, Jardine MJ et alii
Haemodialysis duration, frequency and intensity for end-stage kidney disease

Journal articles
2020
Cochrane Database of Systematic Reviews
Clase CM, Fu EL, Joseph M et alii
Cloth Masks May Prevent Transmission of COVID-19: An Evidence-Based, Risk-Based Approach

Journal articles
2020
Annals of internal medicine
Shaman AM, Smyth B, Arnott C et alii
Comparative efficacy and safety of bp-lowering pharmacotherapy in patients undergoing maintenance dialysis: A network meta-analysis of randomized, controlled trials

Journal articles
2020
Clinical Journal of the American Society of Nephrology

Meg Jardine's Publications

Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial

SGLT2 inhibitors may offer benefit beyond diabetes

Comparison of Circulating Biomarkers in Predicting Diabetic Kidney Disease Progression With Autoantibodies to Erythropoietin Receptor

An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials

Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes

The International Society of Nephrology Advancing Clinical Trials (ISN-ACT) Network: current activities and future goals

Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program

Acute interstitial nephritis and nephrogenic diabetes insipidus following treatment with sulfamethoxazole-trimethoprim and temozolomide

Sodium-glucose co-transporter-2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and meta-analysis

Effects of canagliflozin in patients with baseline eGFR <30 ml/min per 1.73 m2: Subgroup analysis of the randomized CREDENCE trial

How Do the Recent Major Randomized Controlled Trials Inform Best Use of the Novel Glucose-Lowering Agents?

Prevalence, incidence and risk factors of diabetes in Australian adults aged ≥45 years: A cohort study using linked routinely-collected data

Early change in albuminuria with canagliflozin predicts kidney and cardiovascular outcomes: A post hoc analysis from the Credence trial

A randomized trial on the effect of phosphate reduction on vascular end points in CKD (improve-CKD)

Response to: Loutradis et al. Longer Dialysis Sessions Improve Cardiac Systolic Function by Reducing Myocardial Stunning

Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial

Therapy escalation following an elevated hba1c in adults aged 45 years and older living with diabetes in Australia: A real-world observational analysis

The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program

Identifying critically important cardiovascular outcomes for trials in hemodialysis: An international survey with patients, caregivers and health professionals

Forgotten Technology in the COVID-19 Pandemic: Filtration Properties of Cloth and Cloth Masks—A Narrative Review

International consensus definitions of clinical trial outcomes for kidney failure: 2020

Kidney and cardiovascular protection with SGLT2 inhibitors: lessons from cardiovascular outcome trials and CREDENCE

No evidence of a legacy effect on survival following randomization to extended hours dialysis in the ACTIVE Dialysis trial

Haemodialysis duration, frequency and intensity for end-stage kidney disease

Cloth Masks May Prevent Transmission of COVID-19: An Evidence-Based, Risk-Based Approach

Comparative efficacy and safety of bp-lowering pharmacotherapy in patients undergoing maintenance dialysis: A network meta-analysis of randomized, controlled trials

The George Institute for Global Health

The George Institute country sites: